Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
about
Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis.Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.Managing multiple myeloma in elderly patients.Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.Impact of lenalidomide-based induction therapy on the mobilization of CD34(+) cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study.Melphalan hydrochloride for the treatment of multiple myeloma.Prospective Identification of Oligoclonal/Abnormal Band of the Same Immunoglobulin Type as the Malignant Clone by Differential Location of M-Spike and Oligoclonal Band.Therapy sequencing strategies in multiple myeloma: who, what and why?Current applications of multiparameter flow cytometry in plasma cell disorders.Autologous transplant for myeloma: when the old meets the new.Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation.Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.The proteasome and proteasome inhibitors in multiple myeloma.Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.International variations in the use of haematopoietic cell transplantation for haematological malignancies: the effects of national transplant indications tables and differing access to therapies.Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.Expressed fusion gene landscape and its impact in multiple myeloma.Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle.FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma.MRD in multiple myeloma: more questions than answers?Case Report of IgM Multiple Myeloma: Diagnosing a Rare Hematologic Entity.A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.The evolution of stem-cell transplantation in multiple myeloma.[Multiple myeloma : What has been confirmed in therapy?]Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.Multiple Myeloma Index for Risk of Infection.One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myelomaTrial watch: Immunogenic cell death induction by anticancer chemotherapeuticsMultiple myeloma: 2018 update on diagnosis, risk‐stratification, and managementBortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myelomaDeferred autologous stem cell transplantation in systemic AL amyloidosisTherapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92
P2860
Q36396166-529B2A9C-9A16-4E1C-A9E0-DEEA49E0BE6EQ38371861-3E38970E-FFFA-480C-809C-971AC6A3A021Q38605484-450E7109-61B8-47C4-8E76-8175994CFA51Q38662385-CAA90492-23F0-460C-8065-3F2E7C149885Q38691698-BCB38942-4AA5-4193-AD75-5994A46BB9FBQ38704146-4FAE7CBD-B04B-43C3-9492-BC4642BC1BC8Q41353932-D1B4BDD1-5F5B-42D6-8C2C-B60EBC532C1FQ45946305-6525DE04-1350-4F60-9A48-A784DCA8B751Q47110039-2D22231E-085F-44D9-A636-12564E75A85BQ47153254-26116C5A-386A-45D8-AF00-38584D6A5588Q47164979-9B8EC717-634C-4928-9CEC-BC0F9971829BQ47207279-409F8823-C995-4147-8394-EF6E075AFD3DQ47307819-C77FD718-3DDF-48C4-AA94-7923C057ED40Q47339695-1BE74E48-0225-4AF0-91DC-0FB8D01F0D2FQ47418005-08752428-8C4B-4708-B035-BFECBF60F8F3Q47562378-40EC4920-7552-4504-93A9-6B91844EB8A6Q47565618-FE7007A1-072B-4BF3-8402-34EDF7206F3BQ47630577-134E7C5A-5ED8-478A-9424-9D4B2BF1432CQ47794767-B0661986-2287-4AAA-A003-D33D63561A89Q47855599-834E2190-FC6D-49A7-BB1C-3E8402FAE8CBQ48013706-54E7FFFB-8FAB-40D7-B794-9687A2D2A1AFQ48139344-FA41E40B-0B2A-4F85-A598-FAC0DBED3B57Q48193638-2C529A47-7FBC-4FCF-A862-474D486293B6Q50020987-CDB10D9D-5125-4DFC-BEDF-048AE61BE495Q50036381-959E29F7-44AA-46EA-BB2C-96FF72B61C46Q50042721-C41C2332-C94F-4B2B-A2C7-964747FE8345Q50057591-CF9BEA5E-CF86-4FB2-BD69-CBB45B80148CQ50108261-2AF95C8B-B646-48A3-9D78-3C8140B31490Q50225359-04BBF217-2939-4940-8D37-F1D6DD678697Q52715329-094A39C1-D472-4B53-AE4A-9A6600392D23Q52817414-130283D1-E972-4D44-8EEF-C785B31DA16FQ53831599-8CCE16FA-4809-4635-8949-A331BA4EED84Q55322497-AF83F652-FB47-46C5-A3A9-E6E608A6E01AQ55332380-9FFB7085-E50E-4050-BB75-B7DE0B8BB76FQ56528114-87F12DCC-532F-4A4E-9084-1E2076C76A2BQ56594845-F6D59E59-29E8-40DD-BE38-101683D113C2Q58565204-E45D9163-78AA-4E9E-8FF9-CE3E61C658ECQ58575863-5A874CA8-BA23-467A-8681-57D8FF053FC1Q58609453-CAAF978C-469E-4008-997B-7297D3E79B6CQ58761702-2A86A8D5-954D-4D2D-A196-95F3933FB268
P2860
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
@en
type
label
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
@en
prefLabel
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
@en
P2093
P50
P356
P1476
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
@en
P2093
Andrea A Zeytoonjian
Bertrand Arnulf
Catherine Payen
Claire Mathiot
Cyrille Hulin
Denis Caillot
Edie A Weller
IFM 2009 Study
Jean P Fermand
Jean-Luc Harousseau
P304
P356
10.1056/NEJMOA1611750
P407
P50
P577
2017-04-01T00:00:00Z